Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 77 FCF Margin % is 15.55% as of Mar. 2026, which is 5% below its 10-year median of 16.30. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.56 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Getein Biotech ranks better than 95.71% on this metric.
The historical rank and industry rank for Getein Biotech's FCF Margin % or its related term are showing as below:
SHSE:603387'
s FCF Margin % Range Over the Past 10 Years
Min: 5.48 Med: 16.3 Max: 31.59
Current: 26.16
During the past 13 years, the highest FCF Margin % of Getein Biotech was 31.59%. The lowest was 5.48%. And the median was 16.30%.
SHSE:603387's FCF Margin % is ranked better than 95.71% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: -0.56
vs SHSE:603387: 26.16
The historical data trend for Getein Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Getein Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a FCF Margin % of 15.55% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Getein Biotech and its competitors. This is near median its historical median of 16.30. Over the past decade, Getein Biotech's FCF Margin % has ranged from 5.48 to 31.59. According to the industry distribution chart, Getein Biotech ranks #35 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Getein Biotech's FCF Margin % too high?
Getein Biotech's current FCF Margin % of 15.55% is near median its 10-year median of 16.30. Over the past 10 years, this metric has ranged from a low of 5.48 to a high of 31.59. Based on the distribution chart, Getein Biotech ranks #35 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #35 out of 816 companies for FCF Margin %. This places Getein Biotech in the top 4% of its industry — outperforming the majority of peers. Historically, Getein Biotech's own FCF Margin % has ranged from 5.48 to 31.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Getein Biotech and its competitors. Getein Biotech's current FCF Margin % is 15.55%, which is near median its own 10-year median of 16.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.56, compared to a current price of ¥8.90 — trading 17.7% above its estimated fair value. The current FCF Margin % is 15.55%, which is near median its 10-year median of 16.30. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current FCF Margin % is 15.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.7% above its estimated GF Value™ of ¥7.56.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
FCF Margin %: 15.55% (near median its 10-year median of 16.30)
GF Value™: ¥7.56 vs. price of ¥8.90 (17.7% above fair value)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
